Sign in Subscribe
Cancer

Early Detection of HPV-Associated Head and Neck Cancer Using a Novel Liquid Biopsy Tool

Strategic Insights

— 2 min read

Human papillomavirus (HPV) is a significant cause of head and neck cancers in the United States, accounting for approximately 70% of cases. Unlike cervical cancers, there is no standardized screening test for HPV-associated head and neck cancers, often resulting in delayed diagnoses and treatment. Researchers at Mass General Brigham have developed a novel liquid biopsy tool, HPV-DeepSeek, capable of identifying HPV-associated head and neck cancer up to 10 years before symptoms appear. The study, published in the Journal of the National Cancer Institute, demonstrates the potential for early detection and improved treatment outcomes for patients.

Key Takeaways:

  • A novel liquid biopsy tool, HPV-DeepSeek, can detect HPV-associated head and neck cancer up to 10 years before symptoms appear.
  • The test uses whole-genome sequencing to detect microscopic fragments of HPV DNA that have broken off from a tumor and entered the bloodstream.
  • In a study of 56 samples from the Mass General Brigham Biobank, HPV-DeepSeek detected HPV tumor DNA in 22 out of 28 blood samples from patients who later developed the cancer.
  • The test demonstrated 99% specificity and 99% sensitivity for diagnosing cancer at the first time of presentation to a clinic.
  • Machine learning improved the test's power to accurately identify 27 out of 28 cancer cases, including samples collected up to 10 years prior to diagnosis.
  • Researchers are now validating these findings in a second blinded study using hundreds of samples collected as part of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).
  • Daniel L. Faden, MD, FACS, a head and neck surgical oncologist and principal investigator, emphasizes the importance of early detection and hopes that tools like HPV-DeepSeek will allow for treatment interventions at the very earliest stages.

Statistics:

  • Approximately 70% of head and neck cancers in the United States are caused by HPV.
  • The test achieved 99% specificity and 99% sensitivity for diagnosing cancer at the first time of presentation to a clinic.
  • The study included 56 samples from the Mass General Brigham Biobank, with 28 from individuals who developed HPV-associated head and neck cancer and 28 from healthy controls.
  • The earliest positive result for a blood sample was 7.8 years prior to diagnosis.
  • The researchers are currently conducting a second blinded study using hundreds of samples from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

Sources:

  • Faden, D. L., et al. "HPV-DeepSeek: A Novel Liquid Biopsy Tool for Early Detection of HPV-Associated Head and Neck Cancer." Journal of the National Cancer Institute, 2025.
  • National Institutes of Health (NIH). "Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)."
  • Mass General Brigham. "Mike Toth Head and Neck Cancer Research Center."

Read more